Companies Acorda Therapeutics, Inc.
Acorda Therapeutics CEO salary & total pay, FY2022: $984K
Acorda Therapeutics (ACOR) CEO salary, fiscal 2022: Ron Cohen was paid a salary of $625,000 and $984,150 in total compensation. Free brief. Every figure links to the company’s own filing.
Acorda Therapeutics, Inc. no longer files a proxy statement; its last pay data is FY2022.
Ron Cohen's complete compensation dossier
A PDF and a CSV sent to your email: Ron Cohen's pay in every fiscal year Acorda Therapeutics, Inc. reported it, line by line, with Ron Cohen's equity grants and Acorda Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $1,504,419FY2020
- $1,646,404FY2021
- $984,150FY2022
CEO total pay was $984,150 in fiscal 2022, down from $1,646,404 in fiscal 2021.
FY2022: salary $625,000 · bonus $0 · stock awards $0 · option awards $0
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Ron Cohen | $625,000 | $0 | $0 | $0 | $350,000 | $0 | $9,150 | $984,150 |
| President and Chief Executive Officer | ||||||||
| Kerry Clem | 415,000 | 0 | 0 | 0 | 168,075 | 0 | 9,150 | 592,225 |
| Chief Commercial Officer | ||||||||
| Lauren Sabella | 366,000 | 0 | 0 | 0 | 155,124 | 0 | 9,150 | 530,274 |
| Former Chief Operating Officer | ||||||||
| Michael Gesser | 450,000 | 0 | 0 | 0 | 0 | 0 | 9,150 | 459,150 |
| Chief Finance Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2022 total | FY2021 total | FY2020 total | Δ FY2021→2022 |
|---|---|---|---|---|
| Ron Cohen | $984,150 | $1,646,404 | $1,504,419 | ↓ −662,254 |
| Kerry Clem | 592,225 | 662,374 | 603,783 | ↓ −70,149 |
| Lauren Sabella | 530,274 | 810,676 | 758,606 | ↓ −280,402 |
| Michael Gesser | 459,150 | 304,884 | — | ↑ +154,266 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our compensation program reflects a pay-for-performance philosophy designed to provide competitive, market-based total compensation that attracts, retains, and motivates highly-qualified employees. It links short-term and long-term cash and equity incentives to corporate and individual performance and aligns the interests of employees with stockholders to build long-term value.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Arnosti Consulting |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2022
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Kerry Clem | Option | 1,723 | 111 | 81.06 | — |
| Kerry Clem | Option | 1,405 | 1,096 | 3.16 | — |
| Kerry Clem | Option | 3,543 | — | 182.76 | — |
| Kerry Clem | Option | 3,543 | — | 236.28 | — |
| Kerry Clem | Option | 3,188 | — | 214.44 | — |
| Kerry Clem | Option | 2,159 | — | 213.18 | — |
| Kerry Clem | Option | 1,250 | — | 164.85 | — |
| Kerry Clem | Option | 1,967 | — | 146.1 | — |
| Kerry Clem | Option | 9,168 | — | 14.46 | — |
| Lauren Sabella | Option | 6,706 | — | 182.76 | — |
| Lauren Sabella | Option | 5,668 | — | 236.28 | — |
| Lauren Sabella | Option | 5,972 | — | 214.44 | — |
| Lauren Sabella | Option | 4,558 | — | 213.18 | — |
| Lauren Sabella | Option | 1,834 | — | 164.85 | — |
| Lauren Sabella | Option | 6,771 | — | 99 | — |
| Lauren Sabella | Option | 2,198 | — | 81.06 | — |
| Lauren Sabella | Option | 13,334 | — | 14.46 | — |
| Michael Gesser | Option | 21,250 | 63,750 | 3.74 | — |
| Ron Cohen | Option | 6,673 | 447 | 81.06 | — |
| Ron Cohen | Option | 24,993 | 75,007 | 3.64 | — |
| Ron Cohen | Option | 21,250 | — | 182.76 | — |
| Ron Cohen | Option | 16,799 | — | 236.28 | — |
| Ron Cohen | Option | 15,668 | — | 214.44 | — |
| Ron Cohen | Option | 11,455 | — | 213.18 | — |
| Ron Cohen | Option | 4,984 | — | 164.85 | — |
| Ron Cohen | Option | 36,417 | — | 14.46 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| John P. KelleyIndependent · Board Chair · Compensation Committee (Chair) | $124,854 | — | $2,636 | — | — | $127,490 |
| John VarianIndependent · Audit Committee | 81,440 | — | 33,391 | — | — | 114,831 |
| Lorin J. RandallIndependent · Audit Committee (Chair) · Nominations and Governance Committee · Not standing for re-election | 76,000 | — | 2,636 | — | — | 78,636 |
| Peder K. Jensen, M.DIndependent · Audit | 73,392 | — | 2,636 | — | — | 76,028 |
| Sandra Panem, Ph.DIndependent · Compensation · Nominations and Governance (Chair) | 70,000 | — | 2,636 | — | — | 72,636 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2022 |
|---|---|
| Cash retainers and fees | $425,686 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $425,686 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Acorda Therapeutics as a peer
Companies that benchmark against ACOR
No companies currently name ACOR as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Disclosed peer group — fiscal year 2022
The peer group as the company's own proxy names it, the “2022 Peer Group” and “2023 Peer Group” — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Neuronetics, Inc. | 2025 | Keith Sullivan | $728,000 | $3,208,750 | $0 | $412,776 | $4,365,064 |
| 2 | OptiNose, Inc. | 2023 | Ramy Mahmoud | 646,994 | 637,075 | 656,245 | 454,740 | 2,414,265 |
| 3 | Biodesix Inc. | 2025 | Scott Hutton | 643,404 | 356,849 | 524,437 | 710,280 | 2,238,470 |
| 4 | Rockwell Medical, Inc. | 2025 | Mark Strobeck | 566,500 | 612,040 | 249,732 | 453,200 | 1,895,472 |
| 5 | Acorda Therapeutics, Inc. | 2022 | Ron Cohen | 625,000 | 0 | 0 | 350,000 | 984,150 |
| 6 | Alimera Sciences, Inc. | 2022 | Richard Eiswirth | 580,000 | 124,000 | 242,329 | 0 | 964,198 |
| 7 | Aytu BioPharma, Inc. | 2026 | Joshua Disbrow | 608,154 | 42,750 | 0 | 177,000 | 844,854 |
| — | Redhill Biopharma Ltd. | — | — | — | — | — | — | not in coverage universe |
| — | Biocept Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Prophase Labs, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Journey Medical Corp. | — | — | — | — | — | — | not in coverage universe |
| — | Lucira Health, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Acorda Therapeutics, Inc. | not disclosed | Option 100 | not disclosed | Arnosti Consulting |
| Alimera Sciences, Inc. | not disclosed | Option 75 · Restricted Stock 25 | not disclosed | not disclosed |
| Aytu BioPharma, Inc. | 50% | not disclosed | not disclosed | Alvarez and Marsal Holdings, LLC |
| Biocept Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Biodesix Inc. | 110% | not disclosed | not disclosed | not disclosed |
| Journey Medical Corp. | not disclosed | not disclosed | not disclosed | not disclosed |
| Lucira Health, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Neuronetics, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| OptiNose, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Prophase Labs, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Redhill Biopharma Ltd. | not disclosed | not disclosed | not disclosed | not disclosed |
| Rockwell Medical, Inc. | not disclosed | not disclosed | not disclosed | Compensia |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2023 | 2023-06-22 | 5,543,869 | 4,749,896 | 18,183 | 53.86% | Passed |
| 2022 | 2022-06-10 | 3,405,934 | 1,250,124 | 53,602 | 73.15% | Passed |
| 2021 | 2021-06-02 | 3,083,087 | 256,247 | 34,060 | 92.33% | Passed |
| 2019 | 2019-06-19 | 37,961,055 | 637,577 | 3,694,730 | 98.35% | Passed |
| 2018 | 2018-06-27 | 32,317,200 | 6,432,183 | 29,952 | 83.4% | Passed |
| 2017 | 2017-05-31 | 36,450,950 | 1,042,382 | 13,867 | 97.22% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2023 | 2023-06-22 | 53.86%a |
| 2022 | 2022-06-10 | 73.15%b |
| 2021 | 2021-06-02 | 92.33%c |
a. Approved under the standard stated in the filing — “If a quorum is present, the votes cast "for" must exceed the votes cast "against" to approve, on an advisory basis, the compensation of our Named Executive Officers. || Abstentions: Abstentions and broker non-votes are not counted as votes "for" or "against" this proposal.”.
b. Approved under the standard stated in the filing — “If a quorum is present, the votes cast "for" must exceed the votes cast "against" to approve, on an advisory basis, the compensation of our Named Executive Officers. || Abstentions: Abstentions and broker non-votes are not counted as votes "for" or "against" this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions and broker 4 non-votes are not considered votes "FOR" any candidate or as a "WITHHELD" vote and therefore will not affect the outcome of this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 5 : 1 |
|---|---|
| CEO total compensation | $984,150 |
| Median employee compensation | $218,380 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2022 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dividend-equivalent accruals | 2023-06-22 | — | 4,800 | — | — | 4 insiders, 4 accrual rows | ||
| Thomas M. Burns | Director | 2023-06-22 | A | 2,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 5 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Peder Jensen | Director | 2023-06-22 | A | 1,200 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| John P. Kelley | Director | 2023-06-22 | A | 1,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Panem Phd | Director | 2023-06-22 | A | 1,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Varian | Director | 2023-06-22 | A | 1,200 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas M. Burns | Director | 2023-06-22 | A | 2,400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Sources (27 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Ron Cohen. DEF 14A, filed 2023-04-27. Section “Summary Compensation Table” · page 41. As printed: 984,150. View filing ↗
- Section 01, Kerry Clem. DEF 14A, filed 2023-04-27. Section “Summary Compensation Table” · page 41. As printed: 592,225. View filing ↗
- Section 01, Lauren Sabella. DEF 14A, filed 2023-04-27. Section “Summary Compensation Table” · page 41. As printed: 530,274. View filing ↗
- Section 01, Michael Gesser. DEF 14A, filed 2023-04-27. Section “Summary Compensation Table” · page 41. As printed: 459,150. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2023-04-27. Section “CEO Pay Ratio”. As printed: 5 : 1. View filing ↗
- Section 08, John P. Kelley. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 127,490. View filing ↗
- Section 08, John Varian. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 114,831. View filing ↗
- Section 08, Lorin J. Randall. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 78,636. View filing ↗
- Section 08, Peder K. Jensen, M.D. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 76,028. View filing ↗
- Section 08, Sandra Panem, Ph.D. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 72,636. View filing ↗
- Section 02, Peder Jensen 2023-06-22. Form 4, filed 2023-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John P. Kelley 2023-06-22. Form 4, filed 2023-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandra Panem Phd 2023-06-22. Form 4, filed 2023-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Varian 2023-06-22. Form 4, filed 2023-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas M. Burns 2023-06-22. Form 4, filed 2023-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-27. Item 5.07 · say-on-pay result. As reported: 53.86% (votes for as printed: 5,543,869). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-06-13. Item 5.07 · say-on-pay result. As reported: 73.15% (votes for as printed: 3,405,934). View filing ↗
- Section 06, 2021 vote. Form 8-K, filed 2021-06-04. Item 5.07 · say-on-pay result. As reported: 92.33% (votes for as printed: 3,083,087). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 425,686 + equity 0 + all other 0 = 425,686, summed across the director compensation table rows.
- Neuronetics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Neuronetics, Inc.'s own proxy. As printed: 4,365,064. View filing ↗
- OptiNose, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in OptiNose, Inc.'s own proxy. As printed: 2,414,265. View filing ↗
- Biodesix Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Biodesix Inc.'s own proxy. As printed: 2,238,470. View filing ↗
- Rockwell Medical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Rockwell Medical, Inc.'s own proxy. As printed: 1,895,472. View filing ↗
- Acorda Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2023-04-27. CEO total compensation as printed in Acorda Therapeutics, Inc.'s own proxy. As printed: 984,150. View filing ↗
- Alimera Sciences, Inc., Section 10b CEO total. DEF 14A, filed 2023-06-29. CEO total compensation as printed in Alimera Sciences, Inc.'s own proxy. As printed: 964,198. View filing ↗
- Aytu BioPharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-22. CEO total compensation as printed in Aytu BioPharma, Inc.'s own proxy. As printed: 844,854. View filing ↗